Transaction DateRecipientSharesTypePriceValue
14th September 2020Owen B. Wallace6,350Exercise of derivative$7.84$49,784.00
9th September 2020Rock Ventures Iii, L.P. Third1,000,000Other acquisition or disposition$0.00
28th July 2020Rock Ventures Iii, L.P. Third875,000Conversion of derivative$0.00
28th July 2020 Sanofi81,250Open or private purchase$16.00$1,300,000.00
28th July 2020Rock Ventures Iii, L.P. Third4,508,333Conversion of derivative$0.00
28th July 2020 Sanofi438,875Conversion of derivative$0.00
28th July 2020Rock Ventures Iii, L.P. Third39,216Conversion of derivative$0.00
24th July 2020Plc Glaxosmithkline1,260,504Open or private purchase$2.25$2,836,134.00
21st July 2020Plc Glaxosmithkline361,111Open or private purchase$18.00$6,499,998.00
21st July 2020Plc Glaxosmithkline348,469Conversion of derivative$0.00
Fulcrum Therapeutics
Fulcrum Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015.

Ticker: FULC
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1680581
Employees: 73
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags